News
New study finds AstraZeneca booster generates higher antibodies against Omicron
AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria.